Madelon Engels

Madelon Engels

Auto-generated profile, based on publicly available information

Madelon Engels

Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center+ , P. Debyelaan 25, Maastricht 6229 HX

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2018 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
JLJia Liu
Jia Liu
LVLinda Volkers
Linda Volkers
WJWanchana Jangsangthong
Wanchana Jangsangthong
CBCindy I Bart
Cindy I Bart
MEMarc C Engels
Marc C Engels
AVAntoine de Vries
Antoine de Vries
The generation of homogeneous cardiomyocyte populations from fresh tissue or stem cells is laborious and costly. A potential solution to this problem would be to establish lines of immortalized cardiomyocytes. However, as proliferation and (terminal) differentiation of cardiomyocytes are mutually exclusive processes, their permanent immortalization causes loss of electrical and mechanical functions. We therefore aimed at developing conditionally immortalized atrial myocyte (iAM) lines allowing toggling between proliferative and contractile phenotypes by a single-component change in culture medium composition. Freshly isolated neonatal rat atrial cardiomyocytes (AMs) were transduced with a lentiviral vector conferring doxycycline (dox)-controlled expression of simian virus 40 large T antigen. Under proliferative conditions (i.e. in the presence of dox), the resulting cells lost most cardiomyocyte traits and doubled every 38 h. Under differentiation conditions (i.e. in the absence of dox), the cells stopped dividing and spontaneously reacquired a phenotype very similar to that of primary AMs (pAMs) in gene expression profile, sarcomeric organization, contractile behaviour, electrical properties, and response to ion channel-modulating compounds (as assessed by patch-clamp and optical voltage mapping). Moreover, differentiated iAMs had much narrower action potentials and propagated them at >10-fold higher speeds than the widely used murine atrial HL-1 cells. High-frequency electrical stimulation of confluent monolayers of differentiated iAMs resulted in re-entrant conduction resembling atrial fibrillation, which could be prevented by tertiapin treatment, just like in monolayers of pAMs. Through controlled expansion and differentiation of AMs, large numbers of functional cardiomyocytes were generated with properties superior to the differentiated progeny of existing cardiomyocyte lines. iAMs provide an attractive new model system for studying cardiomyocyte proliferation, differentiation, metabolism, and (electro)physiology as well as to investigate cardiac diseases and drug responses, without using animals.

7 October 2025 in EP Europace
Verified
Journal Article
Open access
MGMonika Gawałko
Monika Gawałko
ZHZarina Habibi
Zarina Habibi
DVDominique V M Verhaert
Dominique V M Verhaert
MEMadelon Engels
Madelon Engels
Jerremy WeertsJerremy Weerts
Jerremy Weerts
Dominik LinzDominik Linz
Dominik Linz
Aims: Identifying risk or probability of heart failure with preserved ejection fraction (HFpEF) in patients with atrial fibrillation (AF) is challenging. This study aimed to assess the prevalence and factors associated with elevated left atrial pressure (LAP) in AF patients undergoing catheter ablation and to evaluate the concordance between elevated LAP and HFpEF risk scores. Methods and results: This study included 336 symptomatic AF patients (median age 65 years, 41% female) undergoing catheter ablation. Elevated LAP was defined as a mean LAP ≥ 15 mmHg. High HFpEF probability was defined by H2FPEF ≥ 6 and/or HFA-PEFF ≥ 5. Elevated LAP was present in 37% (n = 125) of patients, and factors associated with elevated LAP included higher body mass index (BMI; OR 1.21, 95% CI: 1.11–1.31) and lower LA reservoir strain (OR 0.97, 95% CI: 0.94–0.99). General anaesthesia and non-sinus rhythm were linked to higher LAP but not independently; AF type showed no effect. Among 204 eligible patients, 36% had a high HFpEF probability. Over 12 months, AF recurrence (26% vs. 24%, P = 0.775) and repeat ablations (11% vs. 7.2%, P = 0.230) were similar regardless of LAP status, but severe adverse events (death, life-threatening situations, hospitalizations, or persistent disability) were more common in those with elevated LAP (6.7% vs. 1.7%, P = 0.044). Conclusion: Over one-third of catheter ablation patients had elevated LAP. Poor agreement between elevated LAP and HFpEF risk scores suggests that using these risk scores may not be advisable in AF population.


19 July 2025 in European Journal of Cardiovascular Nursing
Verified
Journal Article
Open access
Dominik LinzDominik Linz
Dominik Linz
JGJolanda Gulpen
Jolanda Gulpen
MEMadelon Engels
Madelon Engels
JHJeroen M.H Hendriks
Jeroen M.H Hendriks
FTFleur Tjong
Fleur Tjong
Sing-Chien YapSing-Chien Yap
Sing-Chien Yap